Clinical Trial

Regorafenib in Patients With Refractory Primary Bone Tumors

Study acronym: Regbone
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options using advanced molecular diagnostics for patients who have not responded to the standard therapeutic regimen, and to introduce modern diagnostics for risk stratification and for the use in molecularly targeted therapies.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-24; most recent amendment 2026-03-24.
Status change: Recruiting → Active, Not Recruiting 2025-04-09
Trial Details
NCT Number NCT05395741
Lead Sponsor Institute of Mother and Child, Warsaw, Poland
Collaborators: Maria Sklodowska-Curie National Research Institute of Oncology
Conditions Osteosarcoma, Ewing Sarcoma of Bone
Enrollment 30 participants
Start Date 2022-04-28
Primary Completion 2025-09-12 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-25